Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Vestibular schwannoma (acoustic neuroma), drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No approved drug for NF2-related schwannomatosis; bevacizumab is off label and its effect wanes.
Predicting which small tumours will grow, so that the rest can be left alone.
Preserving hearing: each option trades tumour control against hearing and facial nerve function.
Rare malignant transformation after radiosurgery in NF2 is not well quantified.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Brigatinib produced radiographic responses in 10 percent of target tumours and 23 percent of all tumours, slowed growth of every tumour type and improved hearing in 35 percent of eligible ears in 40 heavily pretreated patients.
Plotkin and colleagues (NEJM) report the first platform trial in the condition.
A milestone in how this cancer is treated.
Plotkin and colleagues (NEJM).
Trofatter and Rouleau identify the merlin tumour suppressor on chromosome 22.